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The “Harm Reduction” session was chaired by Dr Jacques Normand, Director of the AIDS
Research Program of the United States National Institute on Drug Abuse. The three pre-
senters (and their presentation topics) were: Dr Don Des Jarlais (High coverage needle/
syringe programs for people who inject drugs in low and middle income countries: a
systematic review), Dr Nicholas Thomson (Harm reduction history, response, and current
trends in Asia), and Dr Jih-Heng Li (Harm reduction strategies in Taiwan).
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. Open access under CC BY-NC-ND license.1. Introduction Medical Center, New York City, USA and a professor atHarmreduction refers to policies, programs, andpractices that
aim primarily to reduce the adverse health, social, and eco-
nomicconsequencesof theuseof legaland illegalpsychoactive
drugs without necessarily reducing drug consumption. Major
harm reduction strategies for opioid-dependent users or in-
jection drug users (IDUs) include opiate substitution therapy
(OST) and needle/syringe programs (NSPs) [1].2. Presentations
2.1. The harm reduction experience in low- and middle-
income countries
Dr Des Jarlais is Director of Research for the Baron Edmond de
Rothschild Chemical Dependence Institute at Beth IsraelDrug Abuse, 6001 Execu
J. Normand).
ministration, Taiwan. PublColumbia University Medical Center in New York, USA. Dr
Jarlais’ talk focused on the effectiveness of NSPs and OST in
low- and middle-income countries (LMICs) and transitional-
economy countries, based on a systemic literature review
using PRISMA (Preferred Reporting Items for Systematic Re-
views and Meta-Analyses) guidelines [2]. Primary study data
included coverage of NSP programs and changes in human
immunodeficiency virus (HIV) and hepatitis C virus (HCV)
infection over time among persons who inject drugs in LMICs
and transitional-economy countries. Additionally, changes in
retention of OST participants over time were also collected. A
total of 17 countries were represented in the systematic re-
views of NSP and OST programs in LMICs, including,
Bangladesh, Brazil, China, Estonia, Iran, Lithuania, Taiwan,
Thailand, and Vietnam. A majority of these studies showed
decreases in HIV/HCV prevalence during and after full
implementation of structural level NSPs. OST programs intive Boulevard, MSC 9581, Bethesda, MD 20892, USA.
ished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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pants, similar to studies in high-income countries. These data
generally support the effectiveness of these harm reduction
programs in LMICs and transitional-economy countries.
Nevertheless, it is important to continue monitoring and
evaluating these programs, and when programs are not as
effective as they could be, to identify and correct contributing
factors.
2.2. The harm reduction experience in the Asian region
Dr Nicholas Thomson is a joint director of the Centre for Law
Enforcement and Public Health and has joint appointments at
Johns Hopkins School of Public Health in Baltimore, MD, USA,
and theSchoolofPopulationandGlobalHealthat theUniversity
of Melbourne, Melbourne, Australia. In his talk, Dr Thomson
providedahistorical accountof theevolutionofharmreduction
as well as the current trends in Asia. Years of experience and
observation suggest that the evolution of harm reduction in
Asia is really a recursive journey through four interconnected
main themes: (1) harm reduction programs, (2) research, (3)
policy, and (4) advocacy. Historically, due to the often-strict
enforcement of national antinarcotic laws, harm reduction re-
sponses to HIV driven by injecting drug use have been slow.
They began in Nepal in 1991 with the first needle exchange
project and quickly expanded to Thailand, India, and the
Philippines. These initial needle exchangeprojectsweremostly
created by dedicated individuals from nongovernmental orga-
nizations. The partnership between nongovernmental organi-
zations and researchers produced early results, making it clear
that preventing HIV meant embracing harm reduction.
With the initial success in reducing HIV infection came a
scaling up of other components ofHIVprevention among IDUs,
including increased availability of OST programs. Considerable
funds tosupport theprogramsbecameavailableas theresearch
activities and networks developed. There also have been spe-
cific shifts from criminal justice to health-oriented approaches
in HIV strategies. Currently, many countries in the region have
adopted harm reduction as part of their national AIDS strategy
and increasingly as part of their national drug strategy. How-
ever, there remain many challenges. For example, the overall
coverage of services in the region remains poor. The increase of
amphetamine-type stimulants represents continuing chal-
lenges to both the lawenforcement andpublic health sectors. It
is critical to scale-up the various partnerships between law
enforcement, criminal justice, public health, and civil society,
in the context of the provision of universal access for all key
affected populations, so as to achieve improved public health
and reduced criminal activities.
2.3. Harm reduction strategies in Taiwan
Dr Jih-Heng Li is Professor of Toxicology and Dean of the Col-
lege of Pharmacy at Kaohsiung Medical University in Taiwan.
Hewas formerly theDirector General of theNational Bureau of
Controlled Drugs at Taiwan’s Department of Health during
1994e2005. In his talk, which was based on his chapter “From
gradual prohibition to harm reduction: the experience of drug
policyand lawreforminTaiwan” in thebookDrugLawReform in
East and Southeast Asia published by Lexington Books in August2013 [3], Dr Li described how Taiwan has encountered three
major waves of drug epidemics in its short recorded history of
some 400 years. Each was tackled with different but harm-
reduction-oriented strategies. The first wave was opium
smoking during the Japanese Colonial Period (1895e1945). The
gradual prohibition policy was adopted by the colonial gov-
ernment from 1897 through 1930. Such a policy, which sup-
plied opium to addicts using an opium licensing system, was
similar to present-day methadone maintenance treatment
programs and gradually resulted in a controllable situation.
In contrast to the first wave that was caused by a tradi-
tional cropped drug, the secondwave was due to the deluge of
a synthetic drug, methamphetamine, in the early 1990s.
Methamphetamine is a Schedule II controlled substance in the
1971 United Nations (UN) Convention on Psychotropic Sub-
stances. However, due to Taiwan’s deprivation of UN mem-
bership since 1971, the 1971 Convention was not
implemented. Therefore, law reform became a high priority of
the new drug policy in Taiwan. A new “Act for Prevention and
Control of Illicit Drug Hazard” was enacted in 1998 to
encompass the spirit of all three UN antidrug conventions.
Meanwhile, the new act also granted an illicit drug user the
status of “diseased offender”, which allows addicts to seek
treatment in government-designated hospitals without being
reported or indicted. Control of precursors such as ephedrine
and pseudoephedrine, which are used in the clandestine
laboratories to manufacture illicit methamphetamine, was
also regarded crucial. In the late 1990s, a leveling-off was
observed in the population of methamphetamine users
seeking treatment in all psychiatric hospitals.
However, in theearly2000s, the thirdwaveappeared,notably
with the abuse of club drugs such as “ecstacy”, ketamine, and
some benzodiazepines, as well as the escalation of HIV/AIDS
infection among heroin IDUs. In August 2005, a national pilot
harm reduction program, with measures including NSPs and
methadone maintenance treatment programs, was therefore
initiated in four of 25 administrative areas. One year after the
pilot harm reduction program, a dramatic 10% decrease in all
newHIV seropositive caseswas reported by the TaiwanCenters
forDiseaseControl (CDC), andsubsequently, anationwideharm
reduction program was implemented. In addition to the harm
reduction policy, other measures, including HIV education pro-
grams and HIV testing of drug users, were also found essential
for the effective control of the spread of HIV.
Each of these threewaves of drug epidemics in Taiwanwas
caused by an individual drug that posed a unique problem and
required differential policies. Although problems related to
illicit drugs will probably linger in the future, the Taiwan
experience has clearly shown that the harm reduction policy,
with its core humanistic values and public-health-oriented
and pragmatic efforts, is the key to cost effectively man-
aging drug problems.3. Discussion
Major discussion points of the session were as follows.
(1) Was there much variability in program characteristics in
the studies included in Dr Jarlais’ review, for example,
j o u r n a l o f f o o d and d ru g an a l y s i s 2 1 ( 2 0 1 3 ) s 1 0es 1 2S12secondary exchange and dose? There was not much vari-
ability in NSP because the study was restricted to include
large programs with a structured level of intervention, but
secondary exchange was in all of them. There was more
variability in OST in terms of program policy, procedures,
and/or quality of counseling, but not themeanmethadone
dose, because these clinics all complied with the World
Health Organization guidelines. The variation in OST
retention was substantial; however, most research studies
did not provide a sufficient description of their programs
or eligibility criteria to allow the analyses.
(2) Given that there are many research activities and net-
works working on harm reduction in Asia, are there efforts
to standardize the measures or harmonize across the
network? Dr Thomson agreed that there is a lot of
networking and activities, but often it requires taking
some people in certain sectors out of their comfort zones,
for example, a public health researcher may not be able to
figure out what is important to the police. He suggested
that what is needed is a multidisciplinary action research
team that is also practical and relevant for other sectors.
(3) In Taiwan, harm reduction phases appeared to be driven
by the nature of the drug at the time, to which different
arms of the government responded. Is that an accurate
observation? Dr Li felt that each wave of the response re-
flected the political context and pragmatic purpose at the
time (e.g., the third wave of harm reduction was initiated
to address the HIV issue, not the drug abuse issue).
(4) The Cochrane Review has indicated that no clinical trial
has been conducted on harm reduction. Is such a trial
needed? Two responses were given by Dr Jarlais: the re-
sults of his study will go into the Cochrane Library. With
respect to the clinical trial, because its purpose is to isolate
a single variable to test its effects, it would be unethical
and/or not feasible to isolate and test this public health
approach as a single variable. Dr Normand reminded the
audience that the Institute of Medicine has recently
reached similar conclusions to what Dr Jarlais provided.
(5) How do we preserve successful programs? Dr Jarlais
responded. The answer to this question varies from locale
to locale, and looking at HCV is critical because it may leadto high mortality e even worse than HIV. There have been
situations in which services have been cut and a disaster
follows; such events make policymakers realize the need
to maintain these programs.
(6) Law enforcement is critical but how do we engage it? One
intervention is to legalize NSPs and OST; then law
enforcement will follow the law. The second would be to
provide relevant training and education for law enforce-
ment to learn about harm reduction and HIV prevention.
Another suggestion is to work with higher-level policy-
makers. If the country does not have such programs and
policies in place, they need to be implemented e and
police officers will obey the law. Additionally, we should
consider what might be the benefit for the police officer.
The partnership needs to make it work to be a winewin
situation.
(7) In addition to public health and public safety, we were
reminded that there are other stakeholders, such as those
in housing, health, education, and religious institutions
that need to be considered.
(8) Has the systematic review considered mortality as the
outcome of harm reduction strategies? This has not been
done yet. Dr Jarlais’ next study has shown improvements
in results from the Addiction Severity Index and quality of
life indicators.r e f e r e n c e s
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